What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies?

Journal of Chemotherapy
X ChengJ Kavanagh

Abstract

The aim of this retrospective analysis was to investigate the efficacy and adverse effects of the monoclonal antivascular endothelial growth factor antibody bevacizumab (Avastin(R)) combined with chemotherapeutic agents in non-protocol patients with recurrent ovarian, fallopian tube, or primary peritoneal malignancies. Using our databases, we identified patients treated with bevacizumab combination therapy since June 2005. Responses were evaluated with Response evaluation Criteria in Solid tumors and serum CA125 Rustin criteria. Toxicity was assessed according to the Common toxicity Criteria (CTC) v.3.0. Data from 64 patients were included. The median patient age was 58 years, and they had undergone a median of 4.5 (range, 1-10) prior cytotoxic chemotherapy regimens. The median length of follow-up was 8 months (range, 2-29). The most commonly used combinations were bevacizumab plus taxanes (26.6%) and plus cyclophosphamide (26.6%). A median of 4 cycles of therapy with a median bevacizumab dose of 3,600 mg (range, 500-18,240) were administered. An overall response rate of 21.3% was observed in 13 patients with partial response, and another 42.6% of patients had stable disease. Among the patients with elevated pretreatment serum ...Continue Reading

References

Dec 1, 1982·American Journal of Clinical Oncology·M M OkenP P Carbone
May 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gordon J S Rustin
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Feb 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathy D MillerHope S Rugo
Mar 11, 2006·Gynecologic Oncology·David E CohnJeffrey M Fowler
Jul 19, 2006·Gynecologic Oncology·Carol Aghajanian
Jul 25, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·J D WrightD G Mutch
Oct 24, 2007·Gynecologic Oncology·Robert C BastRichard Pazdur
Nov 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert A BurgerJoel I Sorosky
Nov 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen A CannistraWilliam McGuire
Jan 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suresh S RamalingamUNKNOWN Eastern Cooperative Oncology Group
Jan 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Agustin A GarciaAmit M Oza

❮ Previous
Next ❯

Citations

Jul 8, 2011·Cancer Management and Research·Gina M Mantia-SmaldoneAnda M Vlad
Oct 14, 2014·World Journal of Surgical Oncology·Ying Ma, Wei Duan
Nov 3, 2011·Current Oncology Reports·Marcia Hall, Gordon Rustin
May 31, 2013·Asia-Pacific Journal of Clinical Oncology·Despina HandoliasDanny Rischin
Sep 9, 2011·The Cochrane Database of Systematic Reviews·Kezia GaitskellJo Morrison
Oct 21, 2011·Journal of Clinical Pathology·Jay D NaikTimothy J Perren

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Adenocarcinoma, Clear Cell

Clear Cell Adenocarcinoma is a tumor that arises in the female genital tract and is characterized by cells that appear clear under the microscope. Discover the latest research here.